GB0225908D0 - Treatment of female sexual dysfunction - Google Patents

Treatment of female sexual dysfunction

Info

Publication number
GB0225908D0
GB0225908D0 GBGB0225908.3A GB0225908A GB0225908D0 GB 0225908 D0 GB0225908 D0 GB 0225908D0 GB 0225908 A GB0225908 A GB 0225908A GB 0225908 D0 GB0225908 D0 GB 0225908D0
Authority
GB
United Kingdom
Prior art keywords
treatment
sexual dysfunction
female sexual
female
dysfunction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0225908.3A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Ltd
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Priority to GBGB0225908.3A priority Critical patent/GB0225908D0/en
Publication of GB0225908D0 publication Critical patent/GB0225908D0/en
Priority to AU2003274476A priority patent/AU2003274476A1/en
Priority to PCT/IB2003/004791 priority patent/WO2004041259A1/en
Priority to US10/699,602 priority patent/US20040132697A1/en
Priority to TW092130838A priority patent/TW200420543A/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GBGB0225908.3A 2002-11-06 2002-11-06 Treatment of female sexual dysfunction Ceased GB0225908D0 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
GBGB0225908.3A GB0225908D0 (en) 2002-11-06 2002-11-06 Treatment of female sexual dysfunction
AU2003274476A AU2003274476A1 (en) 2002-11-06 2003-10-27 Treatment of female sexual dysfunction
PCT/IB2003/004791 WO2004041259A1 (en) 2002-11-06 2003-10-27 Treatment of female sexual dysfunction
US10/699,602 US20040132697A1 (en) 2002-11-06 2003-10-31 Treatment of female sexual dysfunction
TW092130838A TW200420543A (en) 2002-11-06 2003-11-04 Treatment of female sexual dysfunction

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0225908.3A GB0225908D0 (en) 2002-11-06 2002-11-06 Treatment of female sexual dysfunction

Publications (1)

Publication Number Publication Date
GB0225908D0 true GB0225908D0 (en) 2002-12-11

Family

ID=9947333

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0225908.3A Ceased GB0225908D0 (en) 2002-11-06 2002-11-06 Treatment of female sexual dysfunction

Country Status (4)

Country Link
AU (1) AU2003274476A1 (en)
GB (1) GB0225908D0 (en)
TW (1) TW200420543A (en)
WO (1) WO2004041259A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111134894A (en) * 2020-01-17 2020-05-12 上海长海医院 Sampling method for in vivo determination of continuous dynamic free drug concentration of canine prostate tissue

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
JP2007516949A (en) * 2003-07-16 2007-06-28 ファイザー・インク Treatment of sexual dysfunction
TW200530235A (en) 2003-12-24 2005-09-16 Renovis Inc Bicycloheteroarylamine compounds as ion channel ligands and uses thereof
US7793137B2 (en) 2004-10-07 2010-09-07 Cisco Technology, Inc. Redundant power and data in a wired data telecommunincations network
US7745451B2 (en) 2005-05-04 2010-06-29 Renovis, Inc. Tetrahydronaphthyridine and tetrahydropyrido[4,3-d]pyrimidine compounds and compositions thereof useful in the treatment of conditions associated with neurological and inflammatory disorders and dysfunctions
CA2617546C (en) 2005-08-03 2014-07-15 Boehringer Ingelheim International Gmbh Use of flibanserin in the treatment of obesity
EP1945214A1 (en) 2005-10-29 2008-07-23 Boehringer Ingelheim International GmbH Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders
JP2009541443A (en) 2006-06-30 2009-11-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Flibanserin for the treatment of urinary incontinence and related diseases
CL2007002214A1 (en) 2006-08-14 2008-03-07 Boehringer Ingelheim Int PHARMACEUTICAL COMPOSITION IN THE FORM OF COMPRESSED, WHERE AT LEAST THE LENGTH OF THE COMPRESSED IN THE PREVIOUS STATE OF THE APPLICATION IS AT LEAST 7/12 OF THE PILOR DIAMETER OF THE PATIENT AND AFTER INGERING IT IN THE FOOD STATE, THE LENGTH OF THE COMP
CA2660476C (en) 2006-08-14 2015-11-17 Boehringer Ingelheim International Gmbh Formulations of flibanserin and method for manufacturing the same
JP5220746B2 (en) 2006-08-25 2013-06-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Controlled release system and manufacturing method thereof
EP2136639B1 (en) 2007-04-02 2016-03-09 Evotec AG Pyrid-2-yl fused heterocyclic compounds, and compositions and uses thereof
EP2139334B1 (en) 2007-04-17 2013-07-03 Evotec AG 2-cyanophenyl fused heterocyclic compounds, and compositions and uses thereof
CL2008002693A1 (en) 2007-09-12 2009-10-16 Boehringer Ingelheim Int Use of flibanserin for the treatment of selected vasomotor symptoms of hot flashes, night sweats, mood swings, and irritability
ES2761688T3 (en) 2014-11-14 2020-05-20 Follea Int System and method to prevent alopecia
ES2904543T3 (en) 2015-06-11 2022-04-05 ReJoy Treatment of sexual dysfunction

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6294517B1 (en) * 1996-02-02 2001-09-25 Nitromed, Inc. Compositions and kits comprising alpha-adrenergic receptor antagonists and nitric oxide donors and methods of use
GB9700504D0 (en) * 1997-01-11 1997-02-26 Pfizer Ltd Pharmaceutical compounds
JP2002508315A (en) * 1997-12-16 2002-03-19 ファイザー・プロダクツ・インク Effective combinations for the treatment of impotence
WO2000012110A2 (en) * 1998-08-26 2000-03-09 Queen's University At Kingston Use of anti(w)pressor agents for vascular remodeling in genital dysfunction
US6486207B2 (en) * 1998-12-10 2002-11-26 Nexmed (Holdings), Inc. Compositions and methods for amelioration of human female sexual dysfunction
IT1312310B1 (en) * 1999-05-07 2002-04-15 Recordati Ind Chimica E Farma USE OF SELECTIVE 1B ADRENERGIC RECEPTOR ANTAGONISTS TO IMPROVE SEXUAL DYSFUNCTION
US6720001B2 (en) * 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
IL139457A0 (en) * 1999-11-08 2001-11-25 Pfizer Compounds for the treatment of female sexual dysfunction
CN1237060C (en) * 2001-01-02 2006-01-18 弗·哈夫曼-拉罗切有限公司 Quinzolone derivatives as alpha IA/B adrenergic receptor antagonists
JP2003055261A (en) * 2001-08-08 2003-02-26 Pfizer Prod Inc Combination of preparation
GB0206033D0 (en) * 2002-03-14 2002-04-24 Pfizer Ltd Compounds useful in therapy

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111134894A (en) * 2020-01-17 2020-05-12 上海长海医院 Sampling method for in vivo determination of continuous dynamic free drug concentration of canine prostate tissue
CN111134894B (en) * 2020-01-17 2022-02-22 上海长海医院 Sampling method for in vivo determination of continuous dynamic free drug concentration of canine prostate tissue

Also Published As

Publication number Publication date
WO2004041259A1 (en) 2004-05-21
TW200420543A (en) 2004-10-16
AU2003274476A1 (en) 2004-06-07

Similar Documents

Publication Publication Date Title
PL377729A1 (en) Method of the treatment of sexual dysfunction
IL153492A0 (en) Treatment of male sexual dysfunction
HK1040901A1 (en) Treatment of female sexual dysfunction
GB0225908D0 (en) Treatment of female sexual dysfunction
AU2003248888A8 (en) Peptide composition for treatment of sexual dysfunction
EP1617844A4 (en) Treatment of neurological conditions
ZA200410009B (en) Compositions and methods for ameliorating of human female sexual dysfunction
AU2003219981A1 (en) Benzimidazole-derivatives for the treatment of sexual dysfunction
EP1648430A4 (en) Treatment of premature ejaculation
IL162154A0 (en) Prostagandin composition for the treatment of erectile dysfunction
GB0211295D0 (en) Treatment of pain
GB2386555B (en) Treatment of female sexual dysfunction
IL162455A0 (en) Compounds for the treatment of sexual dysfunction
IL166273A0 (en) Methods of treatment of male erectile dysfunction
IL155775A0 (en) Treatment of male sexual dysfunction
PL362980A1 (en) Treatment of sexual dysfunction
AU2003260818A8 (en) Treatment of immune system dysfunction
AP2004003174A0 (en) Treatment of water
IL162822A0 (en) Treatment of male sexual dysfunction
GB0316673D0 (en) Treatment of female sexual dysfunction
GB0108730D0 (en) Treatment of male sexual dysfunction
GB0106167D0 (en) Treatment of male sexual dysfunction
GB0108483D0 (en) Treatment of male sexual dysfunction
GB0120679D0 (en) Treatment of male sexual dysfunction
GB0321308D0 (en) Treatment of sexual dysfunction

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)